Does Rallies show Form 4 insider transactions for XERS?

Yes. Rallies tracks XERS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is XERS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XERS. It does not provide personalized investment advice.

XERS (Xeris Biopharma Holdings, Inc. Common Stock) Stock Analysis - Insider Trades

Xeris Biopharma Holdings, Inc. Common Stock (XERS) is a publicly traded Healthcare sector company. As of May 21, 2026, XERS trades at $6.20 with a market cap of $1.04B and a P/E ratio of 88.21. XERS moved +5.07% today. Year to date, XERS is -12.13%; over the trailing twelve months it is +22.64%. Its 52-week range spans $2.69 to $10.08. Analyst consensus is strong buy with an average price target of $12.25. Rallies surfaces XERS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading XERS stock inside the company?

Recent XERS insider activity includes Hecht Beth sold 16.67K, Hecht Beth sold 16.67K, Brady James Aloysius sold 10.83K, Hecht Beth sold 16.57K, and Hecht Beth sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.

XERS Key Metrics

Key financial metrics for XERS
Metric	Value
Price	$6.20
Market Cap	$1.04B
P/E Ratio	88.21
EPS	$0.07
Dividend Yield	0.00%
52-Week High	$10.08
52-Week Low	$2.69
Volume	1.61K
Avg Volume	0
Revenue (TTM)	$314.85M
Net Income	$12.01M
Gross Margin	0.00%

Recent XERS Insider Trades

Hecht Beth sold 16.67K (~$103.81K) on May 1, 2026.
Hecht Beth sold 16.67K (~$99.86K) on Apr 1, 2026.
Brady James Aloysius sold 10.83K (~$60.04K) on Mar 30, 2026.
Hecht Beth sold 16.57K (~$103.38K) on Mar 2, 2026.
Hecht Beth sold 100 (~$706) on Mar 2, 2026.

Latest XERS News

Xeris Biopharma Tops Q4 EPS Estimates, Reports $85.8M Revenue — Mar 2, 2026
Xeris Biopharma Files Patent Lawsuit, Shares Drop 10.8% on Recorlev Threat — Feb 27, 2026

XERS Analyst Consensus

4 analysts cover XERS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.25.

Common questions about XERS

Who is trading XERS stock inside the company?: Recent XERS insider activity includes Hecht Beth sold 16.67K, Hecht Beth sold 16.67K, Brady James Aloysius sold 10.83K, Hecht Beth sold 16.57K, and Hecht Beth sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for XERS?: Yes. Rallies tracks XERS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is XERS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XERS. It does not provide personalized investment advice.